Literature DB >> 11723285

Polymorphisms in hypocretin/orexin pathway genes and narcolepsy.

B R Olafsdóttir1, D B Rye, T E Scammell, J K Matheson, K Stefánsson, J R Gulcher.   

Abstract

The neuroexcitatory peptide hypocretin and its receptors are central to the pathophysiology of both human and animal models of the disease. In this study of American and Icelandic patients with narcolepsy, the authors found no significant association between narcolepsy and single-nucleotide polymorphisms in the genes for hypocretin or its two known receptors, hypocretin receptor-1 and hypocretin receptor-2.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11723285     DOI： 10.1212/wnl.57.10.1896

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

2.  An approach based on a genome-wide association study reveals candidate loci for narcolepsy.

Authors:  Mihoko Shimada; Taku Miyagawa; Minae Kawashima; Susumu Tanaka; Yutaka Honda; Makoto Honda; Katsushi Tokunaga
Journal:  Hum Genet       Date:  2010-07-31       Impact factor: 4.132

3.  Genomewide association analysis of human narcolepsy and a new resistance gene.

Authors:  Minae Kawashima; Gen Tamiya; Akira Oka; Hirohiko Hohjoh; Takeo Juji; Takashi Ebisawa; Yutaka Honda; Hidetoshi Inoko; Katsushi Tokunaga
Journal:  Am J Hum Genet       Date:  2006-06-13       Impact factor: 11.025

Review 4.  Sleep state switching.

Authors:  Clifford B Saper; Patrick M Fuller; Nigel P Pedersen; Jun Lu; Thomas E Scammell
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

5.  Evaluation of polygenic risks for narcolepsy and essential hypersomnia.

Authors:  Maria Yamasaki; Taku Miyagawa; Hiromi Toyoda; Seik-Soon Khor; Xiaoxi Liu; Hitoshi Kuwabara; Yukiko Kano; Takafumi Shimada; Toshiro Sugiyama; Hisami Nishida; Nagisa Sugaya; Mamoru Tochigi; Takeshi Otowa; Yuji Okazaki; Hisanobu Kaiya; Yoshiya Kawamura; Akinori Miyashita; Ryozo Kuwano; Kiyoto Kasai; Hisashi Tanii; Tsukasa Sasaki; Yutaka Honda; Makoto Honda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2016-06-16       Impact factor: 3.172

6.  CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway.

Authors:  Mona Skard Heier; Tatiana Evsiukova; Steinar Vilming; Michaela D Gjerstad; Harald Schrader; Kaare Gautvik
Journal:  Sleep       Date:  2007-08       Impact factor: 5.849

Review 7.  Narcolepsy in the older adult: epidemiology, diagnosis and management.

Authors:  Sangeeta S Chakravorty; David B Rye
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.

Authors:  Fang Han; Ling Lin; Barbara Schormair; Fabio Pizza; Giuseppe Plazzi; Hanna M Ollila; Sona Nevsimalova; Poul Jennum; Stine Knudsen; Juliane Winkelmann; Cristin Coquillard; Farbod Babrzadeh; Tim M Strom; Chunlin Wang; Michael Mindrinos; Marcelo Fernandez Vina; Emmanuel Mignot
Journal:  Sleep       Date:  2014-10-01       Impact factor: 5.849

9.  Genome-wide analysis of CNV (copy number variation) and their associations with narcolepsy in a Japanese population.

Authors:  Maria Yamasaki; Taku Miyagawa; Hiromi Toyoda; Seik-Soon Khor; Asako Koike; Aino Nitta; Kumi Akiyama; Tsukasa Sasaki; Yutaka Honda; Makoto Honda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2014-04-03       Impact factor: 3.172

Review 10.  OX1 and OX2 orexin/hypocretin receptor pharmacogenetics.

Authors:  Miles D Thompson; Henri Xhaard; Takeshi Sakurai; Innocenzo Rainero; Jyrki P Kukkonen
Journal:  Front Neurosci       Date:  2014-05-06       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.